THE MEDICAL NEWS

Higher baseline plasma p-tau217 was associated with greater 5- and 10-year risks of cognitive impairment and faster cognitive decline among 2,684 cognitively unimpaired adults. Very high levels corresponded to an estimated 38% risk at five years, but selected cohorts and limited long-term data mean routine screening and individualized prediction remain premature.

For decades, medicine has chased a simple but elusive goal of delivering the right drug to the right place at the right time.

A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.

Loss of one copy of the DNA Ligase I (LIG1) gene in triple-negative breast cancers (TNBC) with TP53 mutations confers resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions have identified a vulnerability in these cells and used it to their advantage.

The Society's Clinical Practice Guideline on testosterone replacement therapy in men with hypogonadism offers recommendations on appropriate testing and prescribing practices.

Researchers have uncovered a novel biological pathway that can lead to seizures when disrupted. The findings also provide a new approach to improve the diagnosis of epilepsy, for which a genetic cause cannot be found in about 50 % of individuals with the condition

Researchers developed ALADYNOULLI, a Bayesian generative model that combines longitudinal health records, age, and polygenic risk to identify reproducible disease signatures across more than 683,000 participants. In UK Biobank testing, the framework achieved stronger short- and long-term risk discrimination than established clinical scores while revealing disease subgroups and genetic association…

As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University study that analyzed national trends in GLP-1 use and spending between 2017 and 2022.